G1VE TECHNOLOGIES

Code to Cure: How AI is Ending Diseases That Have Killed Billions

W.B. Carrington, MBA, LSSMBB, CTPRA, GRCA, GRCP

Feb 2, 2026

Original source

https://www.linkedin.com/pulse/code-cure-how-ai-ending-diseases-have-killed-billions-w-b--gjybe/

Medicine is at a revolution point. For centuries, drug discovery was alchemy—scientists testing millions of compounds hoping one might work, taking 10-15 years and $2-3 billion to bring a single drug to market. Disease diagnosis was guesswork—doctors interpreting scans and symptoms with 70-80% accuracy, missing cancers until too late, prescribing treatments that worked for some patients but failed for others. Medical research crawled—clinical trials taking years to recruit patients, analyze data, and publish results that were obsolete by the time they reached doctors.

That era is ending. Artificial intelligence is compressing decades of research into months, identifying drug candidates in hours that would take humans years to discover, diagnosing diseases with superhuman accuracy, and personalizing treatments to individual genetic profiles. AI isn't just improving medicine—it's fundamentally rewriting how humans fight disease. The companies and nations deploying AI at scale will cure cancers, eliminate genetic disorders, and extend human lifespan by decades. Those clinging to traditional research methods will watch from the sidelines as competitors dominate the future of healthcare.

This article examines how AI is revolutionizing drug discovery, diagnostics, and personalized medicine—and why the next decade will see more medical breakthroughs than the past century combined.

The Drug Discovery Crisis: Why It Takes 15 Years and $3 Billion to Develop One Drug

Traditional drug discovery pipeline:

1. Target Identification (2-3 years)

- Scientists identify biological target (protein, enzyme, receptor) involved in disease
- Problem: Human body has 20,000+ proteins; identifying which one to target = educated guesswork

2. Lead Discovery (2-4 years)

- Test millions of chemical compounds to find "lead" candidates that interact with target
- High-throughput screening: Robots test 10,000-100,000 compounds/day
- Success rate: 0.01%—99.99% of compounds fail

3. Lead Optimization (2-3 years)

- Modify lead compounds to improve efficacy, reduce toxicity
- Medicinal chemistry: Trial-and-error synthesis of variants

4. Preclinical Testing (1-2 years)

- Test in animals (mice, rats, primates) for safety and efficacy
- Failure rate: 90% of candidates fail preclinical testing

5. Clinical Trials (6-10 years)

- Phase I: Test safety in 20-100 healthy volunteers
- Phase II: Test efficacy in 100-500 patients

- Phase III: Test in 1,000-5,000 patients (randomized controlled trials)
- Failure rate: 90% of drugs entering Phase I fail before FDA approval

6. FDA Approval (1-2 years)

- Regulatory review of all data

Total timeline: 10-15 years Total cost: $2-3 billion (including failures) Success rate: 1 in 10,000 compounds tested becomes FDA-approved drug

The bottleneck: Human intuition can't navigate the complexity. Chemical space (all possible drug-like molecules) contains 10^60 molecules—more than atoms in the universe. Testing them all is impossible. Scientists rely on intuition, prior knowledge, and luck—and fail 99.99% of the time.

AI Drug Discovery: From 15 Years to 18 Months

AI doesn't test compounds randomly—it predicts which molecules will work before synthesis.

How AI accelerates drug discovery:

1. AI Predicts Protein Structures (Replaces Years of Experimental Work)

The problem: Drugs work by binding to proteins. To design effective drugs, scientists need to know protein 3D structure. Traditional method: X-ray crystallography (takes months to years per protein; some proteins can't be crystallized).

The AI solution: AlphaFold (DeepMind, 2020-2024)

AlphaFold uses deep learning to predict protein structure from amino acid sequence—with near-experimental accuracy in hours.

Impact:

- 200 million+ protein structures predicted (covers nearly every protein known to science)
- Open-source database: Scientists worldwide access structures instantly (instead of spending years determining them experimentally)
- Drug target identification accelerated: Researchers identify druggable pockets on proteins in days (instead of months/years)

Case Study: Insilico Medicine – AI-Discovered Drug for Idiopathic Pulmonary Fibrosis (IPF, 2023-2025)

Insilico Medicine used AI to discover INS018_055, a drug candidate for IPF (fatal lung disease; median survival 3-5 years after diagnosis).

AI process:

- Target identification (18 days): AI analyzed biological pathways; identified novel target (specific protein kinase involved in lung fibrosis)
- Lead discovery (46 days): Generative AI designed 30,000 novel molecules predicted to bind target; selected top 78 for synthesis
- Lead optimization (18 months): AI predicted modifications to improve drug properties (potency, safety, bioavailability)
- Preclinical testing (12 months): Validated in animal models

Total time (target identification to clinical trials): 30 months (vs. 5-7 years traditional)

Result (2024): INS018_055 entered Phase II clinical trials—first AI-discovered, AI-designed drug to reach this milestone.
Projected impact: If successful, reduces IPF drug development timeline by 60%; AI-designed drugs could reach patients 5+ years faster than traditional methods.

---

2. AI Generates Novel Drug Candidates (Explores Chemical Space Humans Can't)
Traditional approach: Medicinal chemists synthesize variants of known drugs (incremental improvements).
AI approach: Generative AI designs entirely novel molecules—structures never seen before, optimized for target binding, safety, and manufacturability.
Technology: Generative adversarial networks (GANs), reinforcement learning, transformer models (same architecture as ChatGPT, trained on molecular data instead of text).
Case Study: Recursion Pharmaceuticals – AI Drug Factory (2024-2025)
Recursion operates an AI-powered drug discovery platform:

- Robotic labs: 2 million biological experiments/week (testing how drugs affect cells)
- AI models: Analyze experimental data; predict which molecules will succeed
- Generative AI: Designs novel drug candidates

Results (2024-2025):

- 5 AI-discovered drugs in clinical trials (oncology, rare genetic diseases)
- Pipeline velocity: Recursion advances 1 drug candidate to clinical trials every 6 months (vs. 1 every 3-5 years for traditional pharma)
- Partnership: Roche and Bayer invested $200 million+ (recognizing AI drug discovery advantage)

Economic impact: Recursion's platform reduces drug discovery costs 80% ($400 million vs. $2-3 billion traditional). If scaled industry-wide: $100+ billion annual savings in pharma R&D.

---

3. AI Accelerates Clinical Trials (Identifies Optimal Patient Populations)
Traditional clinical trial challenges:

- Patient recruitment: Takes 6-12 months; 80% of trials delayed due to enrollment issues
- Trial design: One-size-fits-all (same drug, same dose for all patients)
- Failure rate: 90% of drugs fail Phase II/III because they don't work for broad patient populations

AI solution:

- AI analyzes electronic health records (EHRs), genetic data, biomarkers to identify patients most likely to respond to drug
- Precision trial design: Enroll only patients with genetic/molecular profiles matching drug mechanism
- Outcome: Higher success rates, faster enrollment, smaller trial sizes (lower costs)

Case Study: Tempus – AI Clinical Trial Matching (2024-2025)
Tempus built AI platform analyzing 50 million+ patient records to match patients to clinical trials.
How it works:

- Oncologist uploads patient data (tumor genetics, treatment history, biomarkers)
- AI identifies relevant clinical trials (matches patient's molecular profile to trial eligibility criteria)
- Real-time enrollment: Patient enrolled in days (vs. months of manual searching)

Results:

- Clinical trial enrollment time reduced 60% (8 months → 3 months average)
- Trial success rates improved 25% (enrolling genetically matched patients increases likelihood of drug efficacy)
- 300+ hospitals using Tempus (including Mayo Clinic, Northwestern, Duke)

Impact: Faster trials = faster drug approvals = lives saved.

AI Diagnostics: Superhuman Accuracy, Millisecond Speed

AI outperforms human doctors in:

- Radiology: Detecting cancers, fractures, lesions in X-rays, CT scans, MRIs
- Pathology: Identifying cancer cells in tissue biopsies
- Dermatology: Diagnosing skin cancers from photos
- Ophthalmology: Detecting diabetic retinopathy, glaucoma, macular degeneration

How AI achieves superhuman performance:

- Trained on millions of images (vs. human radiologist seeing 50,000-100,000 in career)
- Never fatigued (humans miss things after reading 50+ scans/day)
- Detects subtle patterns invisible to human eye

Case Study: Paige AI – Prostate Cancer Detection (FDA-Approved, 2024)
Paige AI developed AI system to detect prostate cancer in tissue biopsies.
Performance (clinical validation, 2024):

- AI accuracy: 96.2% (detected cancer in biopsy samples)
- Human pathologist accuracy: 86.4% (same samples)
- AI + human (AI-assisted pathologist): 98.7%

FDA approval (2024): First AI pathology system approved for clinical use in U.S.
Outcome:

- 50+ hospital systems deployed Paige AI (2024-2025)
- Estimated impact: Prevent 10,000+ missed prostate cancer diagnoses annually in U.S. (early detection = 99% 5-year survival; late detection = 30%)

Case Study: Google DeepMind – Breast Cancer Detection (2020-2024)
DeepMind trained AI to detect breast cancer in mammograms.
Results (clinical trial, 2024):

- AI reduced false positives 5.7% (fewer women recalled for unnecessary follow-up biopsies)
- AI reduced false negatives 9.4% (fewer missed cancers)
- AI matched or exceeded performance of two expert radiologists

Deployment (UK National Health Service, 2024-2025):

- NHS piloting AI mammography screening in 10 hospitals
- Projected impact: Save 500+ lives annually in UK (by catching cancers earlier)

Global potential: If deployed worldwide, AI mammography could prevent 50,000+ breast cancer deaths annually.

Personalized Medicine: The Right Drug, The Right Dose, The Right Patient

Traditional medicine: One-size-fits-all (same drug, same dose for everyone with a disease).
Problem: Patients respond differently due to genetics, age, comorbidities, lifestyle. 30-50% of patients don't respond to standard treatments.
Personalized medicine: Tailor treatment to individual patient (based on genetics, biomarkers, medical history).
AI's role: Analyze patient data (genome, proteome, medical records, lifestyle) → predict which treatment will work → optimize dosage.
Case Study: Tempus – AI Precision Oncology (2024-2025)
Tempus uses AI to recommend personalized cancer treatments.
How it works:

- Tumor genetic sequencing: Identify mutations driving cancer
- AI analyzes 50 million+ patient records: Find patients with similar genetic profiles; determine which treatments worked for them
- Treatment recommendation: AI suggests therapies most likely to succeed for this patient

Results (clinical validation, 2024):

- AI-recommended treatments: 68% response rate (tumor shrinkage or stabilization)
- Standard-of-care treatments: 43% response rate
- Outcome: AI-guided precision oncology 58% more effective than standard care

Adoption:

- 1,500+ oncologists using Tempus (2025)
- Estimated impact: Extend survival for 20,000+ cancer patients annually

---

Case Study: Foundation Medicine – Genomic Profiling for Cancer Treatment (2024-2025)
Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling (CGP) for cancer patients.
Process:

- Tumor biopsy sequenced (analyze 300+ cancer-related genes)
- AI identifies actionable mutations (druggable targets)

- Report recommends FDA-approved therapies or clinical trials

Results:

- 80% of patients have at least one actionable mutation
- Patients receiving genomically matched therapy: Median survival 3.5 years
- Patients receiving standard therapy: Median survival 2.1 years
- Outcome: Precision oncology extends survival 67%

Insurance coverage (2024-2025): Medicare, major private insurers now cover CGP for advanced cancers (recognizing improved outcomes).

The AI Healthcare Revolution: What's Coming Next

By 2030, AI will:

1. Cure Genetic Diseases

- CRISPR gene editing + AI: AI designs precise genetic edits to correct disease-causing mutations
- Target diseases: Sickle cell anemia, cystic fibrosis, Huntington's disease, muscular dystrophy
- Timeline: First AI-designed gene therapies entering clinical trials now (2025-2026); FDA approvals expected 2028-2030

2. Eliminate Most Cancers

- AI early detection: Catch cancers at Stage 0/I (99% curable)
- AI drug discovery: Design targeted therapies for each cancer subtype
- AI treatment optimization: Personalize chemotherapy, immunotherapy, radiation doses
- Outcome: Cancer becomes chronic manageable disease (like diabetes, hypertension)

3. Extend Human Lifespan

- AI aging research: Identify biological pathways driving aging; design interventions (senolytics, NAD+ boosters, telomerase activators)
- Longevity drugs: First AI-discovered anti-aging drugs entering trials (2025-2027)
- Projected impact: Healthy lifespan extended 10-20 years by 2040

4. Democratize Healthcare

- AI diagnostics deployed globally: Smartphone apps diagnose diseases from photos (skin lesions, eye scans, cough sounds)
- Outcome: Billion+ people in developing countries gain access to expert-level diagnostics (without need for specialist doctors)

The Business and Strategic Implications

For Pharma:

- Adopt AI or die: Companies using AI will develop drugs 5× faster at 1/5 the cost
- Traditional pharma: Lose competitive advantage; acquisition targets for AI-native biotech

For Healthcare Providers:

- AI-augmented clinicians: Doctors using AI outperform those who don't (better diagnosis, treatment selection)
- Liability shift: Soon, not using AI will be medical malpractice (if AI detects cancer doctor misses)

For Governments:

- Accelerate AI drug/device approvals: FDA, EMA must adapt regulations (AI-designed drugs validated faster)
- Fund AI healthcare research: NIH, DARPA invest billions in AI medical R&D

For Patients:

- Demand AI-powered care: Ask oncologist if tumor sequenced; ask radiologist if AI reviewed scan
- Participate in AI clinical trials: Early access to cutting-edge therapies

---

Challenges and Risks

1. Data Privacy

- AI requires massive patient datasets (medical records, genomics)
- Risk: Data breaches, unauthorized use
- Mitigation: Federated learning (AI trains on decentralized data without centralizing it); differential privacy; patient consent frameworks

2. Algorithmic Bias

- AI trained on non-diverse datasets may underperform for underrepresented populations (minorities, women, elderly)
- Example: Early AI dermatology systems less accurate on darker skin tones (trained mostly on light-skinned patients)
- Mitigation: Ensure training datasets represent diverse populations; bias testing before deployment

3. Regulatory Lag

- FDA approval processes designed for traditional drugs/devices; AI systems evolve continuously (software updates)
- Challenge: How to regulate "living" AI systems that improve over time?
- Solution: FDA developing adaptive regulatory frameworks (allow iterative AI updates with post-market surveillance)

4. Doctor Resistance

- Some physicians distrust AI ("black box" models); fear job displacement

- Reality: AI augments doctors, doesn't replace them (human judgment + AI analysis = best outcomes)
- Solution: Medical education must integrate AI literacy; train next generation of AI-native physicians

Thought-Provoking Close & Final Thoughts: Code to Cure—The Future is Now

For the first time in human history, we possess the tools to end diseases that have killed billions. AI is compressing centuries of medical progress into decades. The organizations and nations that deploy AI at scale—in drug discovery, diagnostics, personalized medicine—will dominate healthcare, extend human lifespan, and capture trillions in economic value. Those clinging to traditional methods will be left behind, watching as competitors cure diseases they couldn't.

The code to cure is written in algorithms. The question is: who will deploy it first? 💊🧬

✨Call to Action✨:

Subscribe to my LinkedIn Newsletter for more Future Trends and Insights on/in Regulatory Compliance, A.I. (Artificial Intelligence) Governance/Ethics, Internal/External Audit, TPRM (Third-Party Risk Management), Fintech Innovations, and "all things GRC" (Governance, Risk Management, and Compliance). Let's navigate the future together.

🔍 About the Author:

W.B. Carrington, MBA, LSSMBB, CTPRA, GRCA, GRCP, is a seasoned Artificial Intelligence (A.I.), National Defense and National Security Strategist and Subject Matter Expert (SME) in Governance, Risk, and Compliance (GRC), A.I. Governance/Ethics, Regulatory Compliance, Data Governance, Comprehensive/Integrated Risk Management, and Project/Program Management.

As the Managing Partner at G1VE | Technologies and a Strategic Board Advisor to many multi-domain, cross-industry organizations across both the Public Sector (I.e., Fortune 500 and Fortune 1000 companies) and Private Sector entities, W.B. leverages his extensive experience and deep subject matter expertise to drive innovative solutions that enhance organizational resilience and operational integrity. Connect with W.B. Carrington, MBA, LSSMBB, CTPRA, GRCA, GRCP, on LinkedIn to stay updated on the latest insights and trends in these critical areas.